期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 201, 期 -, 页码 90-94出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2008.04.039
关键词
Myasthenia Gravis treatment; MuSK antibodies; AChR antibodies; Rituximab
资金
- Carolyn Newey
We report the results of treatment with Rituximab in six severe, non-responder MG patients. We treated three AChR+MG and three MuSK+MG patients, representing 2% and 20% of the respective groups of our series. Patients were assessed according to the Myasthenia Gravis Foundation of America (MGFA) recommendations. Antibody titers to AChR and MUSK, lg levels, and IgG Subclasses, were tested before treatment and during a follow-up of 9-22 months. All patients, one class V and five class IVB, improved dramatically, with no side effects. Antibody titers declined in all patients (p=0.006). The decline was significantly better in MuSK + MG patients at 9 months (p=0.046) and correlated with a more Sustained clinical improvement. We did not find any significant changes in IgG4 that could explain the different outcome observed between these two groups. (C) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据